MARKET

HELP

HELP

Helus Pharma Inc
NASDAQ
10.60
-0.12
-1.07%
After Hours: 10.50 -0.1 -0.90% 19:54 10/30 EDT
OPEN
10.53
PREV CLOSE
10.71
HIGH
10.98
LOW
10.42
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
3.760
MARKET CAP
774.07M
P/E (TTM)
-2.4928
1D
5D
1M
3M
1Y
5Y
1D
'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment
Benzinga · 2d ago
Psychedelic: Clearmind completes recruitment for AUD cohort of CMND-100 trial
TipRanks · 2d ago
Helus Pharma Reshapes Board Leadership as Co-Founders Exit Executive Roles
TipRanks · 4d ago
Helus Pharma co-founders step down from executive roles, Lawson named chair
TipRanks · 4d ago
*Helus Pharma Announces Mark Lawson Appointed New Independent Chair of the Board of Directors >HELP
Dow Jones · 5d ago
Weekly Report: what happened at HELP last week (1019-1023)?
Weekly Report · 6d ago
Helus Pharma (HELP) Receives a Buy from Guggenheim
TipRanks · 10/23 12:07
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), AxoGen (AXGN) and Quest Diagnostics (DGX)
TipRanks · 10/23 09:41
More
About HELP
Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005.

Webull offers Helus Pharma Inc. stock information, including NASDAQ: HELP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HELP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HELP stock methods without spending real money on the virtual paper trading platform.